2025 · 3rd Quarter (July 1 - Sep 30)

ULTRAGENYX PHARMACEUTICAL, INC.

Filed by MEHLMAN CONSULTING, INC..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 17, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: MEHLMAN CONSULTING, INC.
Client: ULTRAGENYX PHARMACEUTICAL, INC.
Filing UUID: 9f6d8792-7662-46d8-bc37-a4b094909216
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025. H.R.1509/S. 752 - Accelerating Kids Access to Care Act of 2025. H.R. 1/PL 119-21 - One Big Beautiful Bill Act.

Literal federal measure citations: H.R.1262, S. 932, H.R.1509, S. 752, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.